The federal government faces a daunting fiscal outlook, which makes the budgetary impact of the Patient Protection and Affordable Care Act even more important. The official Congressional Budget Office (CBO) analysis indicates modest deficit reduction over the next ten years and beyond. Holtz-Eakin and Ramlet examine the underpinnings of the CBO’s projection and conclude that […]
Using a variety of empirical specifications, there was no statistically significant evidence that noneconomic damage caps exerted any meaningful influence on the cost of employer-sponsored health insurance. The findings suggest that tort reforms have not translated into insurance savings. Read the full study at Health Services Research here.
Elderly patients’ utilization in the first year of Part D increased compared with that of near-elderly patients by 8.1% for days’ supply and 4.8% for the number of individuals filling prescriptions, and their OOP costs declined by 17.2%. Although elderly patients’ OOP costs in the second year were reduced an additional 5.8%,days’ supply increased by […]
For 42 (38%) of the drugs, there was wide consistency in PDL design, with at least 9 states classifying the drug with the same PDL status. For the other 62% of drugs, there was greater variation, with 2 or more states classifying the drugs differently than the others. Generosity and consistency also varied by therapeutic […]
The objective of this analysis is to simulate the difference between national and state-specific individual insurance markets on take-up of individual health insurance. First, we reviewed the literature to characterize the state-specific individual insurance markets with respect to state regulations and to identify the effect of those regulations on health insurance premiums. Second, we used […]